(Nasdaq: MIRM), a leading rare disease company, today announced that on April 10, 2026, the Compensation Committee of Mirum’s ...

Mirum Pharmaceuticals (NASDAQ: MIRM), a mid-cap biotech, performed well last year and is maintaining that momentum so far in 2026. The company's shares have more than doubled over the trailing ...

Mirum Pharmaceuticals’ MIRM top line is primarily being driven by its lead product, Livmarli (maralixibat), which has seen ...

Vertex Pharmaceuticals (NASDAQ: VRTX) and Mirum Pharmaceuticals (NASDAQ: MIRM) are two biotech stocks that share the same ...

If you are wondering whether Mirum Pharmaceuticals at around US$95.20 is still attractively priced after a strong run, you are not alone. The stock shows a 1.1% decline over the last 7 days, a 5.0% ...

Boston-based Eventide Asset Management sold 114,922 shares of Mirum Pharmaceuticals during the third quarter. Despite the sale, the overall value of the position increased by about $50.70 million from ...

FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that they have entered into a definitive ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® ...

Mirum Pharmaceuticals was profitable in the third quarter. However, top-line growth for the midcap biotech will slow this year. A recent acquisition could also negatively affect the bottom line.

Mirum Pharmaceuticals MIRM has delivered a stellar performance over the past three months. Shares of the company have rallied 35% compared with the industry’s rise of 6.9%. The stock has also ...